AUTORADIOGRAPHIC ANALYSIS OF REGIONAL ALTERATIONS IN BRAIN RECEPTORS FOLLOWING CHRONIC ADMINISTRATION AND WITHDRAWAL OF TYPICAL AND ATYPICAL NEUROLEPTICS IN RATS

被引:58
作者
SEE, RE
TOGA, AW
ELLISON, G
机构
[1] UNIV CALIF LOS ANGELES, SCH MED, DEPT PSYCHOL, LOS ANGELES, CA 90024 USA
[2] UNIV CALIF LOS ANGELES, SCH MED, DEPT NEUROL, NEUROIMAGING LAB, LOS ANGELES, CA 90024 USA
关键词
Autoradiography; chronic neuroleptics; clozapine; dopamine receptors; GABA receptors; haloperidol; raclopride;
D O I
10.1007/BF01245166
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rats were administered haloperidol, clozapine, raclopride, or no drug for 28 days or 8 months. Following a 3 week withdrawal period, in vitro autoradiography was utilized to examine receptor binding for dopamine D2 ([3H]spiperone and [3H]raclopride), dopamine D1 ([3H]SCH23390), GABAA ([3H]muscimol), benzodiazepine ([3H]RO15-1788), and muscarinic ACh receptors ([3H]QNB). [3H]spiperone was elevated in striatal subregions only in haloperidol-treated rats, with the largest increases seen in the 8 month duration animals. Striatal [3H]raclopride binding was increased after both short- and long-term treatment in both haloperidol and raclopride, but not clozapinetreated animals. Clozapine-treated rats showed significant increases in [3H]SCH23390 in the nucleus accumbens after 28-day administration; otherwise no changes were seen for this ligand in any other groups. Increases in [3H]muscimol binding in the substantia nigra reticulata were seen in haloperidol-treated rats after 8 month treatment. Binding of [3H]QNB and [3H]RO15-1788 were not significantly different from control for any of the drug-treated groups. These data suggest that persisting alterations in receptor binding are primarily seen in dopamine D2 and GABA receptors after withdrawal from chronic administration of haloperidol but not the atypical neuroleptics, clozapine and raclopride. © 1990 Springer-Verlag.
引用
收藏
页码:93 / 109
页数:17
相关论文
共 68 条
[1]   CHANGES IN CATALEPSY AND RECEPTOR SENSITIVITY FOLLOWING CHRONIC NEUROLEPTIC TREATMENT [J].
ALLIKMETS, LH ;
ZARKOVSKY, AM ;
NURK, AM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1981, 75 (2-3) :145-147
[2]  
ALTAR CA, 1986, BRAIN RES BULL, V16, P517
[3]  
ALTAR CA, 1988, N-S ARCH PHARMACOL, V338, P162
[4]   SOME ATYPICAL NEUROLEPTICS INHIBIT [H-3] SCH 23390 BINDING INVIVO [J].
ANDERSEN, PH ;
NIELSEN, EB ;
GRONVALD, FC ;
BRAESTRUP, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 120 (01) :143-144
[5]   [H-3]N-PROPYLAPOMORPHINE AND [H-3]-LABELED SPIPERONE BINDING IN BRAIN INDICATE 2 STATES OF THE D2-DOPAMINE RECEPTOR [J].
BATTAGLIA, G ;
TITELER, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1982, 81 (03) :493-498
[6]  
BOYSON SJ, 1988, J PHARMACOL EXP THER, V244, P987
[7]   ANTI-SCHIZOPHRENIC DRUGS - CHRONIC TREATMENT ELEVATES DOPAMINE RECEPTOR-BINDING IN BRAIN [J].
BURT, DR ;
CREESE, I ;
SNYDER, SH .
SCIENCE, 1977, 196 (4287) :327-328
[8]   D1-DOPAMINE AND D2-DOPAMINE BINDING-SITE UP-REGULATION AND APOMORPHINE-INDUCED STEREOTYPY [J].
CHIPKIN, RE ;
MCQUADE, RD ;
IORIO, LC .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1987, 28 (04) :477-482
[9]   SELECTIVE D-1 DOPAMINE RECEPTOR INCREASE FOLLOWING CHRONIC TREATMENT WITH SCH 23390 [J].
CREESE, I ;
CHEN, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 109 (01) :127-128
[10]  
DAWSON TM, 1986, J NEUROSCI, V6, P2352